Medication leaflets

Active substance

Results for the substance rurioctocog alfa pegol

8 results

About this active substance

Rurioctocog alfa pegol is a modified recombinant factor VIII used in the treatment and prevention of bleeding episodes in patients with hemophilia A. It is produced using recombinant technology and is pegylated to extend its plasma half-life, providing longer-lasting protection against bleeding.

Rurioctocog alfa pegol is administered intravenously, typically as part of a prophylactic regimen or to treat acute bleeding episodes. It is also commonly used before surgical procedures to prevent bleeding complications.

Common side effects include injection site reactions, headache, and fever. In rare cases, severe allergic reactions or the development of inhibitors against factor VIII may occur, which can reduce the effectiveness of the treatment. Regular monitoring is essential to ensure the safety and efficacy of the therapy.

Rurioctocog alfa pegol is an advanced therapeutic option for patients with hemophilia A, helping to improve their quality of life by reducing the frequency of bleeding episodes.